187 related articles for article (PubMed ID: 15965967)
21. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
22. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment.
Espinoza S; Manago F; Leo D; Sotnikova TD; Gainetdinov RR
CNS Neurol Disord Drug Targets; 2012 May; 11(3):251-63. PubMed ID: 22483291
[TBL] [Abstract][Full Text] [Related]
23. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
24. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
25. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
Bonifati V; Meco G
Pharmacol Ther; 1999 Jan; 81(1):1-36. PubMed ID: 10051176
[TBL] [Abstract][Full Text] [Related]
26. The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Sovijärvi A; Kaakkola S; Gordin A; Teräväinen H
Clin Neuropharmacol; 2001; 24(1):50-7. PubMed ID: 11290882
[TBL] [Abstract][Full Text] [Related]
27. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
Ivanova SA; Alifirova VM; Pozhidaev IV; Freidin MB; Zhukova IA; Osmanova DZ; Zhukova NG; Mironova YA; Tiguntsev VV; Fedorenko OY; Bokhan NA; Wilffert B; Loonen AJM
J Pharm Pharm Sci; 2018; 21(1):340-346. PubMed ID: 30075828
[TBL] [Abstract][Full Text] [Related]
29. Levodopa: past, present, and future.
Hauser RA
Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
[TBL] [Abstract][Full Text] [Related]
30. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.
Lee MS; Kim HS; Cho EK; Lim JH; Rinne JO
Neurology; 2002 Feb; 58(4):564-7. PubMed ID: 11865133
[TBL] [Abstract][Full Text] [Related]
31. Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.
Andréasson M; Brodin L; Laffita-Mesa JM; Svenningsson P
J Parkinsons Dis; 2017; 7(4):619-628. PubMed ID: 28759974
[TBL] [Abstract][Full Text] [Related]
32. Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.
Dwivedi A; Dwivedi N; Kumar A; Singh VK; Pathak A; Chaurasia RN; Mishra VN; Mohanty S; Joshi D
J Geriatr Psychiatry Neurol; 2023 Mar; 36(2):98-106. PubMed ID: 35603896
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
34. Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease.
Zhang Y; Feng S; Nie K; Zhao X; Gan R; Wang L; Zhao J; Tang H; Gao L; Zhu R; Wang L; Zhang Y
J Neurol Sci; 2016 Oct; 369():347-353. PubMed ID: 27653922
[TBL] [Abstract][Full Text] [Related]
35. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
36. Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson's disease.
Zhao C; Wang Y; Zhang B; Yue Y; Zhang J
Sci Rep; 2020 Jun; 10(1):9521. PubMed ID: 32533012
[TBL] [Abstract][Full Text] [Related]
37. The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
Triantafyllou NI; Kararizou E; Angelopoulos E; Tsounis S; Boufidou F; Evangelopoulos ME; Nikolaou C; Vassilopoulos D
Eur Neurol; 2007; 58(2):96-9. PubMed ID: 17565222
[TBL] [Abstract][Full Text] [Related]
38. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
39. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
Merello M; Lees AJ; Webster R; Bovingdon M; Gordin A
J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):186-9. PubMed ID: 8126502
[TBL] [Abstract][Full Text] [Related]
40. Entacapone in the treatment of Parkinson's disease.
Schrag A
Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
